Schwab US Dividend Equity ETF ( $SCHD ) has fallen by 0.29% in the past week. It has experienced a 5-day net inflow of $393.12 million.
This is due, in part, to market sentiment on some of the ETF’s largest holdings. For example:
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
- Unitedhealth Group Inc. heads into its April 21 Q1 2026 earnings with expectations for flat revenue around $109.5 billion but an 8% drop in EPS to about $6.6, reflecting higher medical costs and cautious 2026 guidance. Despite the stock being down roughly 3% year-to-date, sentiment has improved after a 2.48% Medicare Advantage rate hike for 2027, which boosted shares about 8% and eased fears over long‑term margins.
Analysts remain broadly positive: Morgan Stanley and Bernstein both rate the stock a Buy and see better Medicare Advantage margins, an Optum Health recovery, and AI‑driven efficiencies as key upside drivers. Options pricing implies a milder 6% earnings move versus a 12.5% average, and Wall Street’s Strong Buy consensus with an average ~$366 price target suggests about 16% upside, even as some, like TD Cowen, stay more cautious with Hold ratings.
- Chevron sits at the center of volatile oil markets driven by the U.S.-Iran conflict and shifting expectations around the Strait of Hormuz, with its shares swinging as crude repeatedly jumps above and falls below $100 a barrel. While temporary reopenings and ceasefire hopes have triggered sharp sell‑offs in big oil names, elevated prices overall and supply risks still underpin earnings power for the integrated major.
Wall Street views Chevron as a relative safe haven in this backdrop, noting its limited Middle East exposure and strong upstream and downstream drivers. The stock has gained about 23% year-to-date and sports a roughly 4% dividend yield, with analysts at JPMorgan and BMO among those reiterating Buy ratings and lifting targets toward the low‑$200s, leaving around low‑teens upside and a Strong Buy consensus.
- Texas Instruments was not covered in the supplied news flow, so there were no recent company‑specific developments, earnings updates, or fresh analyst calls to summarize for this report. Investors in the chipmaker should look to other sources for the latest on its demand trends, capital spending plans, and cycle positioning, as these remain the key drivers for semiconductor valuations and long‑term total returns.

